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A B S T R A C T
Arterial hypertension is prevalent in the black population in the United States. It is directly 
related to cardiovascular and kidney damage. Its pathogenesis is complex and includes 
the high incidence of obesity, salt sensitivity and the activation of the renin-angiotensin-
aldosterone system. This complexity requires a therapeutic combination that includes changes 
in dietary habits and appropriate antihypertensive regimes. The International Society of 
Hypertension in Blacks recommends initiating dietary intervention for values of systolic/
diastolic arterial blood pressure above 115/75 mmHg and maintaining arterial blood pressure 
below 135/85 mmHg using appropiate antihypertensive medication. The most adequate 
antihypertensive drug for this population has yet to be determined.
© 2015 Sociedad Española de Nefrología. Published by ELSEVIER ESPAÑA, SLU. Published 
under the terms of the CC BY-NC-ND Licence(http://creativecommons.org/licenses/
by-nc-nd/4.0).
Hipertensión en la población afroamericana: breve examen 
de su epidemiología, patogénesis y terapia
R E S U M E N
La hipertensión arterial es prevalente en la población de raza negra en los EEUU. Presenta una 
relación directa con el daño cardiovascular y renal. Su patogenia es compleja e incluye la alta 
incidencia de obesidad, sensibilidad a la sal, y la consecuente activación del sistema de la 
renina, angiotensina y aldosterona. Eso hace que requiera una combinación terapéutica que 
incluye cambios dietéticos y regímenes antihipertensivos adecuados. La Sociedad internacional 
de la hipertensión en pacientes de raza negra recomienda iniciar dietas de control para 
valores de tensión arterial sistólica/diastólica por encima de los 115/75 mmHg y mantener 
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The prevalence of hypertension (HTN), particularly difficult 
to control blood pressure (BP) and earlier onset of hyperten-
sion, is significantly more common in African Americans (AA) 
than whites. Sub-clinical manifestations of pressure-related 
target organ injury are also more common in AA than 
whites, even at blood pressure levels well below conven-
tional HTN thresholds. This translates in the disproportion-
ate occurrence of adverse subcl inical and cl inical 
pressure-related complications in African Americans that 
are consequence of suboptimal levels of blood pressure con-
trol in those with established HTN coupled with longer dura-
tion of blood pressure over their life span. According to the 
most recent National Health and Nutrition Examination 
Survey (NHANES) data, the proportion of treated patients 
with controlled HTN among blacks were similar to those for 
Hispanics but significantly lower than whites.1 These racial 
differences in control rates cannot be attributed to differ-
ences of awareness and treatment (reportedly been higher 
among blacks), nor the use of nonpharmacological/behav-
ioral management, availability of health-insurance, eco-
nomic barriers, or access to healthcare.2 The pathogenesis 
involves multiple mechanisms with the interaction of dif-
ferent factors like obesity, salt sensitivity, renin angiotensin 
system, and endothelium vascular response among others. 
The International Society on Hypertension in Blacks recom-
mends a blood pressure goal of <130/80 mmHg. The majority 
of AA hypertensive patients will require combination anti-
hypertensive drug therapy to meet BP goals. Monotherapy 
with a thiazide diuretic or a calcium channel antagonist has 
consistently lowered BP in this population. Angiotensin con-
verting inhibitors and angiotensin two blockers could be 
used in combination with diuretics for optimal BP control 
and renoprotection in patients with chronic diabetic and 
non-diabetic kidney disease. The final goal encompasses the 
optimal drug combination for the control of BP and protec-
tion of target-organs. With the influx in Spain of immigrants 
from the African continent and Caribbean countries of 
African ancestry, the present review will try to explore the 
epidemiology, pathogenesis and treatment options in our 
African American (AA) population that will helps us better 
understand and elaborate the best therapeutic options for 
our patients.
Epidemiology
Hypertension in AA is a major clinical and public-health prob-
lem because of the high prevalence and premature onset of 
elevated blood pressure in this population. Moreover, the 
common occurrence of pressure related target organ injury 
and high prevalence of comorbidities such as diabetes mel-
litus and chronic kidney disease, markedly increases the like-
lihood of morbidity and mortality in this group at any given 
blood pressure level (Table 1).
Studies have shown causality between HTN, increased 
Body Mass index (BMI), and Sodium intake in the general 
population. Hypertension in the United States (US) black 
population has been associated with obesity (especially in 
women). Excess dietary sodium intake coupled with salt sen-
sitivity, lower dietary potassium intake, excess alcohol intake, 
and an inadequate intake of dietary fruits and vegetables cor-
relate with this assertion.3
Changes in vascular anatomy can have a deleterious effect 
in blood pressure control and increase the incidence of car-
diovascular events. Risk factors such as arterial stiffening and 
increased peripheral resistance may contribute to the devel-
opment of HTN and cardiovascular disease in the general 
population and particularly in AA.4 Cross sectional studies, 
demonstrate that healthy black men can present with an 
increased degree of carotid hypertrophy, stiffness of the cen-
tral arteries, heightened resistance artery constriction/
blunted resistance artery dilation, and greater arterial wave 
reflection than their white counterparts.5
Ethnicity has played a role in the prevalence of HTN in 
certain geographical areas. Data, demonstrating lower preva-
lence of HTN among populations of African descent from the 
Caribbean and rural continental Africa relative to those in 
the US, supports the hypotheses that environmental factors 
represent an important role in the development of HTN in 
blacks living in the US.6 This geographic variation in HTN 
Table 1 – Epidemiology of hypertension in African Americans
Prevalence Treated Controlled Obesity Female Diabetes MI/Stroke CKD progression
% <140/90% % % % % <2.5 ml/min/year
African Americans 74 94 45 41 64 13 29 37
Non-hispanic Whites 63 92 51 28 61 5 29 33
una tensión arterial por debajo de 135/85 mmHg con el uso de medicación antihipertensiva 
idónea. El fármaco antihipertensivo adecuado está por determinar en esta población. 
© 2015 Sociedad Española de Nefrología. Publicado por ELSEVIER ESPAÑA, SLU. Publicado 
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(MESA), which enrolled 6814 patients from four racial/ethnic 
subgroups (whites, blacks, Hispanics, and Asians) with no 
cardiovascular disease, revealed direct relationship between 
the ventricular mass and well establish risk factors such as 
systolic blood pressure, current smoking, exercise, BMI, and 
diabetes.13
As described above. The cardiovascular and renal conse-
quences of HTN are greater in blacks, relative to their white 
counterparts. Structural vascular abnormalities as well as 
genetic, geographic, and environmental factors may play an 
important role. The relationship between LVH and cardiovas-
cular outcomes is particularly strong. These findings under-
scores the urgent need to successfully treat hypertension in 
the black population with agents that could reverse LVH.
Pathogenesis
There are several pathophysiological mechanisms linked to 
the development of HTN and are disproportionately prevalent 
in selected racial/ethnic groups like AA (Table 2).
Obesity contributes significantly to HTN in all populations. 
Is more prevalent in both AA and Hispanics, particularly in 
women, compared with whites.14 One in six AA women are 
considered extremely obese (BMI>40 kg/m2). This prevalence 
is almost fourfold higher than that of their white or Hispanic 
counterparts. Obesity related physiological effects that con-
tribute to this BP phenotype include; enhanced sympathetic 
activity, altered salt sensitivity, and resistance to antihyper-
tensive drug therapy, not to mention chronic renal injury due 
to glomerular hyperfiltration.15
Salt sensitivity is prevalent in AA, particularly those with 
HTN. Conceptually defined as a rise in BP during salt admin-
istration and/or a fall in BP when it is restricted. Weight loss 
ameliorates salt sensitivity at least among overweight Caucasian 
adolescents.16 Salt sensitivity has also been linked to a lesser 
fall in nocturnal BP (no-dipping) as well as to microalbumin-
uria and other pressure-related target-organ injuries in AA.
The role of the renin-angiotensin system (RAAS) in AA has 
not been clearly defined but the pattern of excessive RAAS 
dependent target-organ injury (LVH, CKD/proteinuria) in AA, 
showcases the importance of the RAAS in this population. This 
does not explain the lack of BP reduction with the use of ACE 
inhibitors compared with diuretics.17 A possible reason is that 
low renin levels increase the vascular production of angiotensin 
II promoting the fibrotic effects of aldosterone. Normotensive 
AA patients present with activation of the RAAS with higher 
aldosterone levels in comparison with whites. and AA with 
non-diabetic nephropathy experience less renal events when 
prevalence could be attributed to differences in body mass 
index (BMI) and dietary sodium: potassium ratio. For example 
higher incidence of HTN have been seen in blacks born in 
southern versus northern states.
In addition to environmental factors, genetic factors can 
contribute to HTN development and progression in blacks. 
Genetic underpinnings that may increase the tendency to 
retain sodium include: Epithelial sodium channel polymor-
phisms leading to cellular sodium transport defects, lower 
levels of renin and kinins and lower levels of natriuretic vaso-
dilator prostaglandins amongst others.3 Multiple single nucle-
otide polymorphisms that may be significant in their 
relationship to systolic blood pressure have been also identi-
fied (SLC24A4 and CACANA1H) and are reasonable potential 
candidates for BP regulation involving sodium, potassium, 
and calcium exchanges.7
Blacks in the US demonstrate excess cardiovascular mor-
bidity and mortality relative to whites.8 In the recent coro-
nary artery r isk development in young adults study 
(CARDIA),9 a long-term multicenter US study that enrolled 
young adults (ages 18-30), the cumulative incidence of sys-
tolic heart failure during 20 years of follow-up was greater 
among blacks (1.1% in black women and 0.9% in black men) 
that among whites (0.08% in white women and 0% in white 
men; P=0.001 for blacks versus whites) and was directly 
related to the increased burden of HTN. Specifically, 75% of 
blacks who developed systolic heart failure had HTN during 
the first 10 years of the study versus only 12% of blacks with-
out HTN (P<0.001). Further, elevated BP remained a signifi-
cant risk factor for systolic heart failure throughout the 
study (P<0.001). In the Jackson cohort of the Atherosclerotic 
Risk in Communities (ARIC) study, which included 1729 
middle-age black subjects, echocardiography revealed a 
prevalence of left ventricular hypertrophy (LVH) of 37% in 
black man and 41% in black women.10 Racial causality was 
not feasible since there were no whites in the cohort. Other 
population-based studies have shown increased prevalence 
of LVH in blacks versus whites. Prevalence that persists even 
after adjustment for conventional demographics and clinical 
risk factors, including age, gender, height, and BMI.11 Left 
ventricular mass and its geometry are independent and 
strong risk factors for cardiovascular morbidity and death. 
The cohort study by Liao et al. evaluated 1089 black patients, 
who underwent both coronary angiography and M-mode 
echocardiography, and found that LVH without coexistent 
obstructive coronary artery disease was associated with 
lower survival rate than patients with single-vessel disease 
and similar survival rate as multiple vessel disease.12 
Baseline data from the Multi-Ethnic Study of Atherosclerosis 
Table 2 – Pathogenesis of Hypertension in African Americans37
p salt sentitivity Less r in nocturnal BP 
(Dipping)
p microalbuminuria r Renin p Aldosterone levels
African Americans +++ +++ +++ +++ +++
Whites + + + + +
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We now present the different therapeutic options by order 
of importance and clinical efficacy. The focus of drug therapy 
in AA is centered on the BP lowering efficacy of single drug 
classes. Unfortunately the majority will not be controlled with 
a single agent. Monotherapy with a thiazide diuretic or a cal-
cium channel antagonist has consistently lowered BP more 
effectively than -blockers, ACE inhibitors, and angiotensin 
II type 1 receptor antagonists.28 As mentioned above, the 
majority of AA hypertensive will require combination anti-
hypertensive drug therapy to control their BP and there are 
no discernable racial/ethnic differences in BP response to 
two-drug antihypertensive therapy if at least one of the drugs 
is either a diuretic or a calcium channel antagonist. Highly 
effective drug combinations contain either a diuretic or a cal-
cium channel antagonist in conjunction with a RAS antago-
nist. In the ACCOMPLISH29 (avoiding cardiovascular events 
through combination therapy in patients living with systolic 
hypertension) study amlodipine plus benazepril showed 
superiority over hydrochlorothiazide (HCTZ) plus benazepril 
combination in the black cohort (n=1416) particularly in 
patients with cardiovascular risk factors and diabetes mel-
litus. Thus, there are a number of relatively ineffective anti-
hypertensive drug combinations that should not be used as 
first line agents to control hypertension (ACE inhibitors or 
ARB alone, peripheral and central-acting adrenergic inhibi-
tors) in this population, except if target organ damage is pres-
ent (CKD, Diabetic nephropathy). It is important to understand 
that the attainment of a clinical benefit is somewhat depen-
dent on patient adherence. This has prompted recommenda-
tions for the use of single-pill fixed dose combinations.
Diuretics play a prominent role in AA with refractory HTN. 
The reason for this is not plasma volume expansion despite 
the prevalence of a salt sensitivity state, since the effect is 
transient in animal and human models of HTN.30 The use of 
more than one diuretic will be needed to control BP particularly 
in patients with estimated glomerular filtration rate <40 ml/
Min (eGFR). Hydroclorothiazide plus an aldosterone antagonist 
or amiloride are used in patients with eGFR>50 mL/min/1.73 m2 
and have shown benefits when combine with loop diuretics, 
particularly in patients with advanced heart failure. In patients 
with eGFR of 30-45 mL/min/1.73 m2, the combination of a 
thiazide and a loop diuretic represents and effective option.31
 In the recent revision of the ISHIB consensus statement 
on the management of hypertension in AA25,32 the use of 
chlorthalidone over HCTZ was favored due to the fact that it 
lowered BP more effectively than HCTZ on a mg per mg basis, 
especially at night (longer half-life). The downside being the 
pill burden, intravascular volume depletion and consequent 
pre-renal azotemia.
Given the high level of pre-treatment salt sensitivity and 
the salt retaining effect of many antihypertensives (particularly 
vasodilators:minoxidil), coupled with the prevalence of obesity 
in this population, comprehensive lifestyle modification that 
entails dietary salt, higher intake of potassium and weight loss 
should be implemented. The ladder could lessen salt sensitiv-
ity and restore the “dipping” nocturnal effect of BP.33
There are multiple side effects that need to be taken in 
consideration when using different antihypertensives agents. 
As previously stated before angiotensin converting enzyme 
treated with an ACE inhibitor.18 Angiotensin two blockers in 
combination with a thiazide diuretic are as effective as calcium 
channel blockers (CCB) and thiazides in reducing BP in obese 
hypertensive AA.19 A combination of a CCB and a RAAS block-
ade in uncontrolled BP(>15/10 mmHg of baseline 130/80) is indi-
cated in AA hypertensives, in the absence of compelling 
indications for another drug class. Paradoxically the hypothesis 
behind vitamin D deficiency and incidence of HTN has been 
linked to activation of the RAAS in this population and its sup-
plementation could suppress its activity and maybe control 
blood pressure.20
The endothelium presents as a target to the deleterious 
effects of RAAS activation. Endothelium-dependent and inde-
pendent vascular responses are abnormal in AA compared 
with whites.21 There are also explanatory data suggesting that 
the bioavailability of nitric oxide is lower in AA than whites 
even though AA have much higher endothelial-derived nitric 
oxide synthase (eNOS) activity.22
Resistant HTN is more prevalent in AA than in Whites.23 
They manifest the characteristics comorbidities (albumin-
uria, depressed kidney function, obesity,target-organ 
injury, diabetes, and severe BP elevations) that have been 
linked to antihypertensive drug resistance and therefore 
lesser HTN control.23 Wether poor BP control reflects true 
resistance HTN or other contributory factors such us lack 
of compliance or low socioeconomic status remains to be 
determine.
Obesity, salt sensitivity, RAAS, and endothelial activation 
represent different factors affecting the pathogenesis of HTN. 
The understanding of how this factors influence BP will guide 
the development of treatment protocols that will optimize the 
way we implement diet, physical activity and drug therapy. 
Elucidating this complex pathogenesis will also help guide 
therapies in the future.
Treatment
Optimal treatment of HTN requires an approach that encom-
passes multifactorial lifestyle modifications (weight loss, 
salt,alcohol restriction, and increased physical activity) plus 
drug therapy. The consensus statement on the treatment of 
HTN in AA from the International Society on Hypertension 
in Blacks (ISHIB) recommends comprehensive lifestyle modi-
fication in all AA with a BP>115/75 mmHg.23 This is the BP 
level above which epidemiological cardiovascular disease risk 
begins its upward inflection. In contrast to the JNC 8 recom-
mendations for the treatment of HTN,24 the ISHIB target BP 
goals remain lower (<130/80 mmHg), especially in certain risk 
groups (CKD,Diabetes,cardiovascular disease).25 The American 
Diabetes Association (ADA) recommends a target BP for dia-
betics of <140/90 mmHg.26 Data that correlates from previous 
studies that showed fewer strokes in cohorts with SBP control 
below 10 mmHg lower than baseline and <120 mmHg respec-
tively.27
There is also convincing data of renal outcomes for attain-
ing mean arterial pressure (MAP) <92 mmHg compared to 
MAP of 102-107 amongst AA with HTN and non-diabetic 
nephropathy (urine protein/creatinine ratio >0.22).18
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multifactorial in nature, complicating therapeutic options 
and requiring a multidisciplinary approach. Emphasis 
should be placed on utilizing the most effective drug com-
bination for the control of BP and protection of target-organs 
in this high risk population. The ISHIB consensus statement 
(Fig. 1) recommends a reduction in the BP target, even for the 
lowest risk AA population (<135/85 mmHg) for primary pre-
vention and <130/80 mmHg for secondary prevention with 
target-organ damage present. As previously stated, this will 
require the use of comprehensive life-style modifications 
coupled with drug therapies tailored to different comorbid-
ities.36
Key points
r Hypertension is prevalent in the African American popula-
tion.
r  Epidemiology is influenced by ethnicity and genetics.
r  Multifactorial pathogenesis influenced by obesity, salt sen-
sitivity, activation of the RAAS, among other causes.
r Therapeutic antihypertensive options similar to whites 
with slight variations in blood pressure goals based on rec-
ommendations from the Internat ional Society of 
Hypertension in Blacks.
inhibitors and angiotensin two blockers could be used in com-
bination with diuretics for optimal BP control and renoprotec-
tion in patients with diabetic and non-diabetic kidney disease. 
The clinician should be aware that angioedema occurs more 
in AA than whites during ACE inhibition treatment. 
Angioedema is less frequent with the use of ARB or direct 
renin inhibitors agents.34
Hypertension treatment in AA has evolved during the 
years. The goal is to use the most effective drug combination 
for the control of BP and protection of target-organs. In order 
to comply with the ISHIB recommendations for reduction of 
BP, optimal management of HTN in AA will require the use 
of comprehensive life style modifications and individualized 
drug combinations.
Conclusion
The prevalence of HTN is higher in blacks than in other race/
ethnic groups, with environmental and genetic risk factors 
playing an important role.35 The cardiovascular and renal 
complications of HTN are also greater in blacks relative to 
their white counterparts. Target organ damage such as LVH 
and renal failure are more common in blacks than whites, 
even after comparable levels of BP.31 The pathogenesis is 
Figure 1 – Treatment of hypertension in African Americans vs Whites. a Albumin:creatinine >200 mg/g, eGFR <60 mL/min 
1.73 m2, left ventricular hypertrophy by electro-echocardiogram. b Heart Failure, CAD, peripheral arterial disease, stroke, 
TIA,abdominal aortic aneurysm. c Calcium channel antagonist. d Renin angiotensin or AT1 receptor blocker. e Agents are 
used with compelling indications.
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Primary Prevention 
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